Mechanistic Insights into the Anticancer Potential of Asparagus racemosus Willd. Against Triple-Negative Breast Cancer: A Network Pharmacology and Experimental Validation Study

<b>Background/Objectives</b>: The present study investigated the anticancer potential of <i>Asparagus racemosus</i> Willd. against triple-negative breast cancer (TNBC) using a combined in silico and in vitro approach. <b>Methods</b>: Network pharmacology identified 115 potential targets shared between <i>A. racemosus</i> phytochemicals and TNBC, highlighting key cancer-related pathways. Molecular docking predicted strong binding affinities between specific phytochemicals (beta-sitosterol, quercetin, and others) and crucial TNBC targets, including AKT1 and ERBB2. <b>Results</b>: Molecular dynamics simulations validated these interactions, demonstrating stable complex formation. In vitro, <i>A. racemosus</i> crude extracts exhibited potent anticancer activity against MDA-MB-231 TNBC cells, showing a dose-dependent reduction in viability (IC₅₀ = 90.44 μg/mL), induction of G1 phase cell cycle arrest, and significant early apoptosis. <b>Conclusions</b>: These integrated findings provide compelling evidence for the anticancer potential of <i>A. racemosus</i> against TNBC, suggesting its promise for further development as a therapeutic strategy.